Not Yet Recruiting

NCT Number: NCT07514325

MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer

Rationale: External beam radiotherapy (EBRT) is an important cornerstone in treatment to reduce locoregional relapse in high(-intermediate) risk endometrial cancer (EC) patients. MR-guided adaptive radiotherapy (MGART) allows for more accurate delivery of radiation beams to the patients by visualizing and correcting for interfraction motion, with subsequent reduction of safety margins around the radiotherapy plan. Objective: The MASTEC study will investigate the safety of hypofractionated MR-guided adaptive radiotherapy in five fractions for elective pelvic nodal and vaginal vault irradiation in endometrial cancer.

Study design: Phase II multicentre intervention study Study population: Patients with endometrial cancer that receive adjuvant EBRT to the pelvic nodal areas and vaginal vault (with or without vaginal brachytherapy).

Intervention (if applicable): MR-guided adaptive radiotherapy (MGART) with reduced PTV margins, including 5 times 6Gy to the vaginal vault and pelvic nodal areas, 2 times a week .

Main study parameters/endpoints: The primary endpoint is acute gastrointestinal and genitourinary toxicity, scored by the Common Terminology Criteria Adverse Events version 6.0. Secondary endpoints are late gastrointestinal and genitourinary toxicity, quality of life and disease free survival; disease-specific survival; overall survival and metastasis-free survival.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Endometrial Cancer Endometrial Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Neoplasms Neoplasms by Site Radiotherapy, Adjuvant Urogenital Diseases Urogenital Neoplasms Uterine Diseases Uterine Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

In order to be eligible to participate in this study, a participant must meet all of the following criteria:

Women aged 18 years or older with histologically proven carcinoma of the endometrium, treated with curative hysterectomy with or without bilateral salpingo-oophorectomy. All histologies may be included (endometrioid, clear cell carcinoma, de-/undifferentiated carcinoma, carcinosarcoma, other non-endometrioid)
Candidate for adjuvant EBRT as decided by multidisciplinary tumour board, amongst others:

FIGO IB grade 3 endometrioid carcinoma
FIGO stage II endometrioid carcinoma
FIGO stage IIIA-C1 endometrioid carcinoma
FIGO IB-II clear cell carcinoma
FIGO IA-III carcinosarcioma
Patients receiving adjuvant systemic therapy are eligible when these therapies will not be administered concurrently
Patients receiving vaginal vault brachytherapy are eligible
Capable of giving informed consent

Exclusion criteria

A potential participant who meets any of the following criteria will be excluded from participation in this study:

Contra-indications for MRI according to the guidelines of the local department of Radiology, inability to lay on a treatment table for 45-60 minutes or severe claustrofobia
Presence of para-aortic lymph node metastases (FIGO stage IIIC2)
Prior pelvic radiotherapy
WHO performance score > 2

Treatment and study plan

MR-guided adaptive radiotherapy (MGART) with reduced PTV margins, including 5 times 6Gy to the vaginal vault and pelvic nodal areas, 2 times a week

Radiation

Patients will be treated with hypofractionated MR-guided adaptive radiotherapy up to 30Gy to the vaginal vault and pelvic nodal areas, contoured on T2W MRI and CT (slice thickness 3mm). Radiotherapy will not be performed on consecutive days. Radiotherapy will be performed by IMRT (7MV) on an MR-linac (Elekta Unity).

Primary outcomes

Acute gastrointestinal and genitourinary toxicity (within 3 months after start of treatment)

Time frame: 5 years after end of treatment
- Primary outcomes:
Acute gastrointestinal toxicity: Maximum CTCAE v6.0 grade of GI toxicity within 90 days after treatment.

Acute genitourinary toxicity: Maximum CTCAE v6.0 grade of GU toxicity within 90 days after treatment.
- Secondary Outcomes Late gastrointestinal toxicity: Maximum CTCAE v6.0 grade between 90 days and 5 years after treatment.
Late genitourinary toxicity: Maximum CTCAE v6.0 grade between 90 days and 5 years after treatment.

Acute vaginal toxicity: Maximum CTCAE v6.0 grade within 90 days after treatment.

Late vaginal toxicity: Maximum CTCAE v6.0 grade between 90 days and 5 years after treatment.

Quality of life: EORTC QLQ-C30 and QLQ-EN24 scores at 6 months and annually up to 5 years.

Locoregional disease-free survival: Time to locoregional recurrence or death. Distant disease-free survival: Time to distant metastasis or death. Overall survival: Time to death from any cause. Endometrial cancer-specific survival: Time to death due to endometrial cancer

Study contacts

Contact information is provided by the study sponsor or research team.

Casper Reijnen, MD, PhD

CONTACT

[email protected]

0031243614505

Heidi Rütten, MD

CONTACT

[email protected]

0031243614505

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Registry information

Official study title

MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer (MASTEC)

Acronym: MASTEC

Important dates

Study start: 2026
Primary completion: 2028
Study completion: 2033
First posted: Apr 7, 2026
Registry last updated: Apr 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting